Grant Opportunities

Research & Synergetic Grants

2025-08-08 | Mariana Boudová, Grant Support Center

Continuous	• Foundation ČEZ - Support for regions for 2024 • NSF - Active Funding Opportunities • EACR - Travel Fellowships • GAČR - Cooperation with Austria (FWF is the lead agency) • GAČR - Cooperation with Germany (DFG is the lead agency) • EMBO - Scientific Exchange Grants 2025 • HORIZON-ERC-POC: HORIZON ERC Proof of Concept Grants • widerAdvance Facility
2025	
August	• ERC-2025-ADG: ERC Advanced Grant 2025 • IBRO - Parenthood Grants
September	• HORIZON-EIC-2025-TRANSITIONOPEN: EIC Transition Open • Major projects 2026 (partner only) • HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorders • HORIZON-HLTH-2025-01-DISEASE-01: Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections • HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders • HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential • HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU) • HORIZON-HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies • HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU) • HORIZON-HLTH-2025-01-TOOL-05: Boosting the translation of biotech research into innovative health therapies • HORIZON-HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs) • HORIZON-HLTH-2025-01-IND-02: Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices • HORIZON-HLTH-2025-03-IND-03-two-stage: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative ("breakthrough") devices • HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health • HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response • HORIZON-HLTH-2025-01-DISEASE-06: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD) • HORIZON-HLTH-2025-01-TOOL-01: Enhancing cell therapies with genomic techniques • Canon Foundation Research Fellowship 2026 • HORIZON-MISS-2025-02-CANCER-01: Sustained collaboration of national and regional cancer funders to support the Cancer Mission through translational research • HORIZON-MISS-2025-02-CANCER-02: Understanding the effects of environmental exposure on the risk of paediatric, adolescent and young adult cancers • HORIZON-MISS-2025-02-CANCER-03: Innovative surgery as the cornerstone of affordable multi-modal therapeutic interventions benefitting cancer patients with locally advanced or metastatic disease • HORIZON-MISS-2025-02-CANCER-04: Investigator-initiated multinational early-stage innovative clinical trials for paediatric cancer • HORIZON-MISS-2025-02-CANCER-05: Pragmatic clinical trials to enhance the quality of life of older cancer patients (65 years and older) through nutrition • Martina Roeselová Memorial Grant 2026 • Brno Ph.D. Talent - 2025
October	• GAČR - Cooperation with Switzerland (SNSF is the lead agency) 2nd call in 2025 • Leveraging Europe's Expertise to accelerate Cell Therapy for Type 1 Diabetes (HORIZON-JU-IHI-2025-11-04-two-stage) • HORIZON-EIC-2025-PATHFINDERCHALLENGES-01-02: Generative-AI based Agents to Revolutionize Medical Diagnosis and Treatment of Cancer • COST Action 2025 • Visegrad Grants 2025 • Visegrad+ Grants 2025 • Visegrad Strategic Grants 2025 • Open Science II (partner only) • DFF-Research Project 2 (2025)

November	• IOCB Tech - Voucher program to bridge funding gaps in clinical research • Fulbright scholarship for researchers and lecturers 2025/2026 • Wellcome - Discovery Awards 2025 (partner only)
December	• AHA - Career Development Award 2025 (partner only)
2026	
March	• Wellcome - Discovery Awards 2026 (partner only)
April	• **2nd round** | HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorders • **2nd round** | HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders • **2nd round** | HORIZON-HLTH-2025-03-IND-03-two-stage: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative ("breakthrough") devices • **2nd round** | HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health • **2nd round** | Leveraging Europe's Expertise to accelerate Cell Therapy for Type 1 Diabetes (HORIZON-JU-IHI-2025-11-04-two-stage)
May	• **2nd round** | Wellcome - Discovery Awards 2025 (partner only)
September	• **2nd round** | Wellcome - Discovery Awards 2026 (partner only)
2029	
Continuous	• ERDERA - Networking Support Scheme

AHA - Career Development Award 2025 (partner only)

Source	American Heart Association (partner only)
Maximum budget amount	231 000 USD (77 000 USD/ year)
Funding (%)	100
Link	https://professional.heart.org/en/research-programs/aha-funding-opportunities/career-development-award
Project duration	3 years
Deadline	2.12.2025 15:00

Description

This grant supports highly promising healthcare and academic professionals, in the early years of one's first professional appointment, to explore innovative questions or pilot studies that will provide preliminary data and training necessary to assure the applicant's future success as a research scientist.
The award will develop the research skills to support and greatly enhance the awardee's chances to obtain and retain a high-quality career position.
At the time of application, the applicant must hold an MD, PhD, DO, DVM, DDS, or equivalent post-baccalaureate doctoral degree.
Mentoring Team: The award requires, at a minimum, a primary mentor and a secondary mentor who will provide counsel and direction and scholarship oversight. Up to two additional mentors may be named to the mentoring team. A mentoring team approach with a committed lead mentor is an essential piece. Applicants should clearly define each person's role as part of the mentoring team. At least one mentor must be from outside of the applicant's department, division or institution.

Brno Ph.D. Talent - 2025

Source	Brno PhD talent
Maximum budget amount	360 000 CZK per 3 years (120 000 CZK per 1 year)
Funding (%)	100
Link	https://www.jcmm.cz/projekt/brno_phd_talent_en/about-project
Project duration	3 years
Deadline	1st round: 23.9.2025 23:59

Description

Brno PhD talent is programe to support individual projects of PhD students.
It offers long-term financial support and a scheme for career development to 25 talented doctoral students through a scholarship of 120,000 CZK per year for 3 years. The selection of beneficiaries is based on the excellent academic track record, experience, and extraordinary activities of the applicants. The quality of the submitted scientific project and the team and facilities are also considered.

The competition is open to all first year doctoral students of four partner universities (focus on a technical and natural sciences)
- Brno University of Technology
- Masaryk University
- Mendel University
- University of Veterinary Sciences Brno

The competition has three rounds:
1. Formal review of applications
2. Expert review of applications
3. Final project presentations

Application:
It describes the Applicant's CV, Scientific Project and Team and Facilities. The maximum length is 12 pages; it is written in English.

Final presentations:
Two external evaluators review every application, and the best-scoring applications pass to the third competition round. The finalists will present their projects to the Expert Committee. One final presentation lasts approximately ten minutes (about six minutes to deliver the application, followed by a four-minute discussion). Apart from evaluating the applicant's professional knowledge and the project proposal in a broader context, the Committee members will also assess the presentation skills, the ability to explain the project contribution and defend its design, personal motivation, reaction time, assertiveness, etc. After hearing all presentations and discussions with each finalist, the Committee will propose the final ranking.

Canon Foundation Research Fellowship 2026

Source	Canon Foundation
Maximum budget amount	30 000 EUR
Funding (%)	100
Link	https://www.canonfoundation.org/programmes/research-fellowships/
Project duration	3-12 months
Deadline	15.9.2025 23:59

Description

Annually, the Canon Foundation in Europe grants up to 15 Fellowships to highly qualified European and Japanese researchers. European Fellows are expected to pursue a period of research in Japan whereas Japanese Fellows are expected to do their research in Europe.
Canon Foundation Fellowships are for a minimum period of three months up to a maximum of one year.
All fields of research are supported. There are no limitations or restrictions. Applicants do not have to be currently enrolled or employed at the time of applying.
Canon Fellows from Europe are free to choose their host institutes and hosts in Japan. The same freedom is given to Japanese Canon Fellows coming to Europe. Canon Foundation Research Fellowships may be applied for when an agreement on cooperation and on a research plan has been reached between the guest researcher and the proposed host institution.
Please note that priority is given to applicants going to Europe and Japan for the first time.

COST Action 2025

Source	COST (European Cooperation in Science and Technology)
Maximum budget amount	130 000 EUR per year max, NO BUDGET for partners, just reimbursement
Funding (%)	100
Link	https://www.cost.eu/funding/open-call-a-simple-one-step-application-process/
Project duration	max 4 years
Deadline	25.10.2025 12:00

Description

COST Actions are Science and Technology (S&T) networks open to researchers and innovators, and other relevant stakeholders, affiliated to a legal entity such as: a public entity (national, regional, local
public authority or any other kind of public entity), universities, research centres, small and medium- sized enterprises (SMEs), large companies, Non-Governmental Organisation (NGOs), as well as any
other form of legal entity recognised under a national or international framework.

COST Actions are Pan-European, Bottom-up, Open throughout their lifetime to new members and are adaptable in terms of internal organisation and strategy; well-suited to promote Multi-, Inter- and
Transdisciplinary collaborations, Output and Impact-Oriented. COST supports networking via different activities such as meetings, short-term scientific missions, training schools and dissemination
products as part of COST Actions, to achieve bottom-up defined challenges. COST does not fund research itself.

DFF-Research Project 2 (2025)

Source	Danmarks Frie Forskningsfond (Independent Research Fund Denmark)
Maximum budget amount	4 400 000 DKK excluding overheads/administration expenses
Funding (%)	100
Link	https://dff.dk/media/4vcadvik/uk_call_for_proposals_independent_research_2025pdf.pdf
Project duration	3 years,but it is possible to apply for a 4-year project if a PhD student is involved in the project
Deadline	7.10.2025 12:00

Description

The objective of DFF-Research Project 2 is to advance the quality of, and develop collaboration within Danish research, DFF offers funding for research projects carried out by multiple researchers (e.g. postdoctoral candidates and PhD students). A DFF-Research Project 2 is often characterised by a coordinated and mutually binding collaboration on a well-defined, joint research question; however, it may also be a project formulated by a single researcher, which is to be carried out in their research team, when it can be argued that the project is particularly ambitious and resource demanding, and that the research objective cannot be obtained
through a DFF-Research Project 1. The research activities must establish synergy among any subprojects, involve international collaboration (if relevant), and be of a high, international standard.

EACR - Travel Fellowships

Source	European Association for Cancer Research - Travel Fellowships
Maximum budget amount	3 500 EUR
Funding (%)	100
Link	https://www.eacr.org/travel-fellowships
Project duration	shor-term visit
Deadline	Continuous

Description

The EACR has joined forces with Worldwide Cancer Research to provide Travel Fellowships of up to 3 500 EUR to enable early-career cancer researchers to gain new skills through a short-term visit to a lab or research group in another country. Please submit your application at least 8 weeks before you plan to start your trip.

EMBO - Scientific Exchange Grants 2025

Source	EMBO
Maximum budget amount	68 to 140 EUR per day based on country
Funding (%)	100
Link	https://www.embo.org/funding/fellowships-grants-and-career-support/scientific-exchange-grants/
Project duration	from 1 week up to 3 months
Deadline	Continuous

Description

EMBO Scientific Exchange Grants fund research exchanges of up to three months between laboratories in eligible countries. The grants facilitate collaborations with research groups with expertise techniques or infrastructure that is unavailable in the applicant's laboratory. They cover travel cost plus subsistence for the fellow.

EMBO Scientific Exchange Grants are awarded for research exchanges between laboratories in EMBC Member States, Associated Member States or Cooperation Partners.
EMBC Member states: Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Lithuania, Luxembourg, Malta, Montenegro, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, and United Kingdom
EMBC Associate Member states: India, Singapore
Co-operation partners: Chile, Taiwan
Only in exceptional cases, the grants be awarded for research visits outside the countries listed above.

The applicant must be an active research scientist at any stage in their career (minimum PhD student level) with a least one year of research experience. In order for the home laboratory to benefit from the exchange, on completion of the fellowship applicants must return to their home laboratory for at least six months.

ERC-2025-ADG: ERC Advanced Grant 2025

Source	Horizon Europe - ERC
Maximum budget amount	2,5 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/ERC-2025-ADG?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=ERC-2025-ADG&isExactMatch=true&status=31094501,31094502,31094503&frameworkProgramm
Project duration	up to 5 years
Deadline	28.8.2025 17:00

Description

ERC Consolidator Grants

Advanced Grants are designed to support excellent Principal Investigators at the career stage at which they are already established research leaders with a recognised track record of research achievements. Applicant Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal.

A competitive Advanced Grant Principal Investigator is expected to be an active and established research leader with a track record of significant research achievements. No specific eligibility criteria with respect to the academic requirements are foreseen. Principal Investigators must provide a list of achievements reflecting their track record.

ERDERA - Networking Support Scheme

Source	AZV
Maximum budget amount	30 000 EUR
Funding (%)	100
Link	https://www.azvcr.cz/vyhlaseni-networkingove-vyzvy-v-ramci-partnerstvi-erdera/
Project duration	45 months
Deadline	Continuous

Description

Through this constantly open call, ERDERA supports the organisation of transnational networking events that promote knowledge sharing, research uptake and collaborations among clinicians, researchers, and patients/patient advocacy organizations (PAOs).

These events will strengthen new or expanding research networks on rare diseases and rare cancers in general and promote the inclusion of typically underrepresented countries (UCs) in European rare diseases and rare cancers networks in particular.

With funding of up to €30 000 per networking event, the scheme is open from May 2025, offering a flexible framework for building the connections essential to meaningful knowledge sharing in rare disease and rare cancers research.

The first aim of the Networking Support Scheme (NSS) is to encourage scientific knowledge exchange on rare diseases or rare cancers between clinicians, researchers, research managers and patients in new and in expanding research networks by funding networking events.

The second aim of the Networking Support Scheme is to enable or increase the participation of usually underrepresented countries in Europe in new and in expanding research networks on rare diseases or rare cancers.

The focus of the networking events should be on research results and their implications, as well as on innovative solutions. The outcomes of these networking events may lead to future collaborative and novel research efforts.

Foundation ČEZ - Support for regions for 2024

Source	Foundation ČEZ - Support for regions
Maximum budget amount	not specified
Funding (%)	100
Link	http://www.nadacecez.cz/cs/vyhlasovana-grantova-rizeni/podpora-regionu.html
Project duration	not specified
Deadline	Continuous

Description

Support Regions - the aim of this programme is to support public benefit projects. The projects submitted may concern support for children and youth, health, social care, people with disabilities, science, education, culture, sport or the environment.

Fulbright scholarship for researchers and lecturers 2025/2026

Source	Fulbright Commission
Maximum budget amount	depends on the country being visited
Funding (%)	100
Link	https://fulbright.gov.cz/stipendia/stipendium-pro-vedce-a-prednasejici/
Project duration	3-10 months
Deadline	1st round: 1.11.2025 23:59

Description

The scholarship supports long-term stays of Czech scientists and university teachers in the USA to conduct research and possibly lecture in any field except clinical medicine.

The length of the stay depends on the project submitted and varies from three to ten months in the academic year.

From 2025/26, the scholarship will be awarded in two categories, with the number of years since obtaining the doctoral degree at the time of the application deadline being decisive:

- Postdoctoral Fellows for those who have obtained their Ph.D. degree no more than 5 years ago at the time of the application deadline
- Senior for those who have obtained their Ph.D. degree or its senior equivalent more than 5 years ago.

Grant content:
- Living expenses fellowship
- Return airfare allowance
- Basic health insurance
- Research and professional development allowance
- The grant also includes small allowances for family members for travel and living expenses. Fellows are responsible for their own health insurance and transportation for their family members.

Basic requirements:
- Czech citizenship
- Very good knowledge of English

Requirements:
- Ph.D. degree or equivalent
- Successful higher education teaching and/or scientific activity in accordance with the ethical principles of scientific work.
- Invitation from the American side.
- Signed consent to the processing of personal data.

Preference is given to applicants who have not worked or lived in the US for a long period of time.

GAČR - Cooperation with Austria (FWF is the lead agency)

Source	GAČR
Maximum budget amount	not determined
Funding (%)	100
Link	https://gacr.cz/vyzva-pro-podavani-projektu-na-principu-hodnoceni-lead-agency-partnerska-organizace-3/
Project duration	24 or 36 months
Deadline	Continuous

Description

The Grant Agency of the Czech Republic (GAČR) announces a call for projects based on the Lead Agency (LA) evaluation principle. The call concerns projects in cooperation with the Austrian Science Fund (FWF). In this call, the FWF agency acts as the LA. This means that project proposals are evaluated by only one agency, which is FWF for this call. The project proposal must be prepared in accordance with the formal guidelines and regulations of the lead agency.
The joint international project must show elements of joint cooperation between teams, the added scientific value of joint research, and the scientific work of both research teams must be closely linked. Project proposals may be submitted to the following fields: (a) technical sciences, (b) life sciences, (c) medical and biological sciences, (d) social sciences and humanities, (e) agricultural and biological-environmental sciences.
The call is continuous. The Czech part of the project proposal must be submitted to the GACR within 7 days of the submission of the project proposal to the FWF. Projects can be bilateral or trilateral (combinations with all agencies with which GACR cooperates under Weave initiative).
Limitation of wages: max. 60 000 CZK per 1,0 FTE, min. workload of proposer 0,2, min. workload of co-proposer 0,1, limits are not set for other team members.

GAČR - Cooperation with Germany (DFG is the lead agency)

Source	GAČR
Maximum budget amount	not determined
Funding (%)	100
Link	https://gacr.cz/vyzva-pro-podavani-projektu-na-principu-hodnoceni-lead-agency-partnerska-organizace-3/
Project duration	24 or 36 months
Deadline	Continuous

Description

The Grant Agency of the Czech Republic (GAČR) announces a call for projects based on the Lead Agency (LA) evaluation principle. The call concerns projects in cooperation with the German Research Foundation (DFG). In this call, the DFG agency acts as the LA. This means that project proposals are evaluated by only one agency, which is DFG for this call. The project proposal must be prepared in accordance with the formal guidelines and regulations of the lead agency.
The joint international project must show elements of joint cooperation between teams, the added scientific value of joint research, and the scientific work of both research teams must be closely linked. Project proposals may be submitted to the following fields: (a) technical sciences, (b) life sciences, (c) medical and biological sciences, (d) social sciences and humanities, (e) agricultural and biological-environmental sciences.
The call is continuous. The Czech part of the project proposal must be submitted to the GACR within 7 days of the submission of the project proposal to the DFG. Projects can be bilateral or trilateral (combinations with all agencies with which GACR cooperates under Weave initiative).
Limitation of wages: max. 60 000 CZK per 1,0 FTE, min. workload of proposer 0,2, min. workload of co-proposer 0,1, limits are not set for other team members.

GAČR - Cooperation with Switzerland (SNSF is the lead agency) 2nd call in 2025

Source	GAČR
Maximum budget amount	not specified
Funding (%)	100
Link	https://gacr.cz/vyzva-pro-podavani-svycarsko-ceskych-projektu-3/
Project duration	24 or 36 months
Deadline	8.10.2025 23:59

Description

The Grant Agency of the Czech Republic (GAČR) announces a call for projects based on the Lead Agency (LA) evaluation principle, with the solution expected to start in 1.7.2026. The call concerns projects in cooperation with the Swiss National Science Foundation (SNSF). In this call, the SNSF agency acts as the LA. This means that project proposals are evaluated by only one agency, which is SNSF for this call. The project proposal must be prepared in accordance with the formal guidelines and regulations of the lead agency.
The joint international project must show elements of joint cooperation between teams, the added scientific value of joint research, and the scientific work of both research teams must be closely linked. Project proposals may be submitted to the following fields: (a) technical sciences, (b) life sciences, (c) medical and biological sciences, (d) social sciences and humanities, (e) agricultural and biological-environmental sciences.
The Czech part of the application can be submitted no later than October 8, 2025 (within 7 days after the official deadline of October 1, 2025, which was set for Swiss applicants by the SNSF agency).
Limitation of wages: max. 65 000 CZK per 1,0 FTE, min. workload of proposer 0,2, min. workload of co-proposer 0,1, limits are not set for other team members.

HORIZON-EIC-2025-PATHFINDERCHALLENGES-01-02: Generative-AI based Agents to Revolutionize Medical Diagnosis and Treatment of Cancer

Source	Horizon Europe - EIC
Maximum budget amount	4 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-EIC-2025-PATHFINDERCHALLENGES-01-02?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&isExactMatch=true&status=31094501,31094502&programmePart=431
Project duration	3 - 5 years
Deadline	29.10.2025 17:00

Description

Imaging is a crucial component of cancer clinical protocols, providing detailed morphological, structural, metabolic, and functional information. However, harnessing the full potential of the data generated through medical imaging in clinical settings remains challenging. Clinicians often struggle to combine diverse and large-scale data into a comprehensive view of patient care, disease progression, and treatment efficacy. The inability to seamlessly integrate and interpret diverse data sources result in suboptimal patient outcomes and inefficiencies in the delivery of healthcare.

The integration of traditional Artificial Intelligence (AI) with medical imaging can transform healthcare, but most existing applications are still in their infancy and must overcome a number of challenges to accelerate adoption. These include AI applications being confined to single data modalities, which restricts their overall effectiveness (Monomodal Application); inadequate and insufficient data training, leading to data scarcity and a lack of generalizability, making them less reliable across diverse patient populations, including with regard to gender-sensitivity; and the lack of AI model interpretability, as many AI systems function as "black boxes," providing little insight into their decision-making processes. This lack of transparency limits trust in the systems and their usability in clinical settings.

The goal of this Pathfinder Challenge is to create interactive GenAI autonomous agents and/or a combination of them (super-agent) that provide clinicians with a holistic end to end perspective of patient care, throughout the entire clinical pathway. These agents aim to enhance pattern identification, reduce inconsistencies and errors in diagnoses as well as improve cancer treatment. While the focus is on GenAI, we also encourage the integration of other advanced AI technologies, such as topological and geometric deep learning, neural fields, graph neural networks, etc., which can complement and enhance the robustness and effectiveness of GenAI-based solutions in addressing the challenges of cancer diagnosis and therapy.

The Challenge will support early-stage groundbreaking research projects that will develop and validate novel approaches and concepts for integrating and interpreting multimodal medical imaging and health data. Additionally, it will involve

generating reliable synthetic medical data, which will also be pooled to form a common database and used for the development of advanced algorithms.

Project proposals under this Challenge should focus on one (and only one) of the following diseases: breast cancer, cervical cancer, ovarian cancer, prostate cancer, lung cancer, brain cancer, stomach cancer or colorectal cancer.

HORIZON-EIC-2025-TRANSITIONOPEN: EIC Transition Open

Source	Horizon Europe - EIC
Maximum budget amount	2,5 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-EIC-2025-TRANSITIONOPEN
Project duration	2 - 6 years
Deadline	17.9.2025 17:00

Description

EIC Transition funds innovation activities that go beyond the experimental proof of principle in laboratory. It supports both the maturation and validation of your novel technology from the lab to the relevant application environments (by making use of prototyping, formulation, models, user testing or other validation tests) as well as explorations and development of a sustainable business case and business model towards commercialisation.

Proposed activities must include further technology development on the results achieved in a previous project and follow user-centric methodologies to increase chances of the innovation's future success in the market. EIC Transition projects should address, in a balanced way, both technology and market/business development, possibly including iterative learning processes based on early customer or user feedback. These activities should include, subject to the level of maturity of the technology, a suitable mix of technology development and validation activities to increase the maturity of the technology beyond proof of concept to viable demonstrators of the technology in the intended field of application (i.e., from TRL 4 up to Technology Readiness Level 5 to 6).

The activities must in all cases address market readiness towards commercialisation and deployment (market research, value proposition, business case and business model, prospects for growth, intellectual property protection, competitor analysis etc.) and aspects of regulation, certification and standardisation (if relevant), aimed at getting both the technology and the business idea investment ready.

HORIZON-ERC-POC: HORIZON ERC Proof of Concept Grants

Source	Horizon Europe - ERC
Maximum budget amount	150 000 EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/ERC-2025-POC?order=DESC&pageNumber=2&pageSize=100&sortBy=startDate&isExactMatch=true&status=31094501,31094502&programmePart=43108406,43108514,43108557,431201
Project duration	18 months
Deadline	Continuous

Description

The ERC Proof of Concept Grants aim at facilitating exploration of the commercial and social innovation potential of ERC funded research and are therefore available only to Principal Investigators whose proposals draw substantially on their ERC

funded research.

Profile of the ERC Proof of Concept Eligible Principal Investigator:
All Principal Investigators in one of the main grants are eligible to participate and apply for an ERC Proof of Concept Grant. Principal Investigators in an ongoing main grant or in a main grant that has ended after 1 January 2024 are eligible to apply. For further information please see the ERC Work Programme 2025.

HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)

Source	Horizon Europe - Health
Maximum budget amount	20 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-CARE-01?keywords=HLTH-2025-01-CARE-01&isExactMatch=true&status=31094501,31094502,31094503&frameworkProgramme=43108390&order=DESC&pageNum
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

This topic will contribute to advancing and generating research to better understand and improve Generative AI-based virtual assistant solutions and their applicability in healthcare settings with the aim of improving patient health outcomes, fostering personalised healthcare and support the resilience, sustainability and efficiency of the healthcare systems. In addition, the topic aims to also cover the understanding and mitigation of possible shortcomings (biases) and frameworks for monitoring and overseeing these solutions' use.
Research actions under this topic should include all the following activities, ensuring multidisciplinary approaches and a broad representation of stakeholders in the consortia (e.g. industry, academia, healthcare professionals, patients):
- Develop virtual assistant solutions based on new or optimised trustworthy Generative AI models
- Demonstrate the added-value and clinical utility of the virtual assistant solutions
- Develop a regulatory strategy and interaction plan with regulators and Health Technology Assessment bodies
- Develop or adapt existing methodologies for continuous assessment of the proposed
Generative AI-based virtual assistant solutions.

HORIZON-HLTH-2025-01-DISEASE-01: Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections

Source	Horizon Europe - Health
Maximum budget amount	15 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-DISEASE-01?order=DESC&pageNumber=1&pageSize=100&sortBy=startDate&keywords=HORIZON-HLTH-2025-01-DISEASE-01&isExactMatch=true&status=31094
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

Proposals should aim to develop phage-based therapies to treat bacterial infections that do not respond to conventional treatment options. For this, applicants should carry out multicenter, multinational randomised controlled clinical trial (RCT) to generate scientific evidence demonstrating safety and efficacy of phage-based therapy as stand-alone or in combination with standard-of-care (such as antibiotic or other innovative non-antibiotic-based treatment) for the treatment of difficult-to-treat bacterial infections.
Both approaches for phage therapy, personalised phage preparations or ready-to-use phage cocktails, are in scope with the call. Innovative study design, aiming at better capturing and evaluating the full potential of the benefit of personalised phage therapy, e.g. using regularly updated phage preparations, is welcome.
The call is open to any pathogen causing difficult to treat infections mainly due to AMR or to biofilms, for any clinical indication and applying phage treatment in any route of administration. Applicants are encouraged to address pathogens listed in the WHO Bacterial Priority Pathogens List.

HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential

Source	Horizon Europe - Health
Maximum budget amount	10 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-DISEASE-03?keywords=HORIZON-HLTH-2025-01-DISEASE-03&isExactMatch=true&status=31094501,31094502,31094503&frameworkProgramme=43108390&orde
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

Proposals should exclusively pursue the development of existing antiviral and prophylactic and therapeutic candidates that are based on antibody and/or antibody-derived proteins targeting at least one of the priority viruses:
- Arenaviridae: Junin mammarenavirus, Lassa mammarenavirus
- Hantaviridae: Hantaan virus, Andes virus, Sin Nombre virus
- Poxviridae: Variola major
- Paramyxo: Hendra, Nipah virus
- Togaviridae: Venezuelan equine encephalitis virus

Proposals are expected to conduct preclinical studies of antibodies and antibody-derived proteins, prepare Good Manufacturing Practice (GMP)86 quality test batches and carry out first in human clinical safety studies. Proposals should include a critical discussion of to what extent the antibodies and antibody-derived proteins would be expected to be amenable to production and distribution at an affordable cost and at a scale sufficient to meet demand in a pandemic.

Proposals should thus aim to diversify and accelerate the global prophylactic and therapeutic research and development portfolio for emerging and re-emerging viral infections, and to strengthen the leading role of the EU in prophylactic and therapeutic research and development.

Proposals may focus either on antibody or on antibody-derived proteins, or both.

HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response

Source	Horizon Europe - Health
Maximum budget amount	8 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-DISEASE-04?order=DESC&pageNumber=1&pageSize=50&sortBy=relevance&keywords=Leveraging%20artificial%20intelligence%20for%20pandemic%20prepa
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

Examples from the COVID-19 pandemic response illustrate how advanced AI tools can enable efficient data use to support areas like forecasting, infectious disease surveillance and monitoring, development of medical interventions, timely diagnosis of infection, disease prognosis, or real-time monitoring of adherence to public health recommendations. New technologies with potentially high impact like air or wastewater real-time monitoring systems have also emerged.

These experiences and advances hold great potential for the future, but additional development and expansion of novel AI-based tools and technologies (including generative AI) is needed, while also further improving and testing existing ones. The use of AI on diverse datasets, as well as on their combinations within and across disciplines, can greatly increase the accuracy of assessments and predictions of medical (pharmaceutical or non-pharmaceutical) interventions in preparedness for, and response to epidemics and pandemics.

Research actions under this topic should include several of the following activities:

- Develop new, or improve existing AI-based tools, methods and technologies, geared towards greater safety, efficiency and impact of medical, societal or logistical countermeasures aiming at the prevention, containment or control of infectious disease epidemics or improved response management of health systems.
- Scout, assemble and prepare appropriate FAIR[1] datasets generated across the EU and Associated Countries (e.g. COVID-19, Influenza, etc.), for the development, training and testing of targeted AI-supported generative assessment and prediction tools, in support of evidence-based policy and decision making for pandemic preparedness and response; in areas like surveillance and monitoring of infectious disease and disease dynamics, facilitating differential diagnosis, triage and risk group predictions, predicting drug response and disease progression, etc.
- Leverage the capacities of the existing and emerging data research infrastructures and the future European Health Data Space (EHDS)[2] and the European Open Science Cloud (EOSC)[3] architectures and research environments, while comprehensively addressing cybersecurity, data privacy, trustworthiness, equity and data quality, interoperability and access modalities.
- Identify and address the current technical, operational, and social limitations related to the (cross-border) access to quality data and to the smooth implementation of AI-driven solutions in the societal and legal context of the EU and Associated Countries.
- Engage with end-users, policymakers, regulatory bodies and authorities, and other stakeholders in the development, improvement, testing and validation of trustworthy and ethical AI-based tools and technologies, to propose options for the validation and uptake of the novel AI tools in real-world settings taking into consideration aspects like training needs, responsible use, users' trust, energy consumption, etc.

HORIZON-HLTH-2025-01-DISEASE-06: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)

Source	Horizon Europe - Health
Maximum budget amount	4 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-DISEASE-06?order=DESC&pageNumber=1&pageSize=50&sortBy=relevance&keywords=Implementation%20research%20addressing%20strategies%20to%20stre
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

The European Commission is a member of the Global Alliance for Chronic Diseases (GACD), an alliance of international funding agencies representing over 80% of the world's public health research funding and the first collaboration of its kind to specifically address NCDs. The GACD supports implementation science to improve health outcomes. This topic is launched in concertation with the other GACD members funding agencies and aligned with the 10th GACD call.
The proposed implementation research should be focused on one or more evidence-based interventions (or complex interventions) focussed on building equity-orientated health systems change to tackle the growing burden of chronic conditions, including NCDs. The choice of intervention(s) and provision of existing evidence of the intervention's effectiveness, cost-effectiveness, sustainability, scalability and potential for long-term health and other impacts should be justified (and in what context this evidence has been generated).
As the evidence underpinning strategies to transform and/or strengthen health systems in the context of NCDs is still emerging, particularly in LMICs, a limited period of testing the effectiveness of an intervention that the applicant's team has adapted for local implementation is therefore usually appropriate.
Applicants should explore the implementation of proposed intervention(s) for a selected study population(s) taking into account the unique social, political, economic, and cultural context(s) in which the study will take place. Applicants should justify why any adaptation will not compromise the known effectiveness of the selected intervention(s).

HORIZON-HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)

Source	Horizon Europe - Health
Maximum budget amount	8 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-IND-01?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2025-01-IND-01&isExactMatch=true&status=31094501,31094
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

The topic focuses on addressing the challenges of ATMP manufacturing, the need for highly specialised equipment and facilities, including in-process quality control and validation tests,
scaling up and batch-to-batch reproducibility, whilst maintaining the efficacy of an ATMP product during the manufacturing process and/or the transition from centralised to

decentralised manufacturing.

This topic aims to optimise the ATMP production where the general manufacturing process for a given medicinal product has already been established but has not been sufficiently optimised for its scale-up. Collaboration is crucial to refine the manufacturing of ATMPs, emphasising advancements in processes - including leveraging the potential of digital tools and advanced sensors -, fostering standardisation and enhancing quality controls for more efficient production and deployment of these innovative therapies, ideally covering the entire manufacturing lifecycle.

HORIZON-HLTH-2025-01-IND-02: Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices

Source	Horizon Europe - Health
Maximum budget amount	4 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-IND-02?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2025-01-IND-02&isExactMatch=true&status=31094501,31094
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination "Maintaining an innovative, sustainable, and competitive EU health industry". To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all the following expected outcomes:

- Notified Bodies (NBs), device[1] developers and manufacturers adopt digitalisation in their conformity assessment procedures thus facilitating device development. As certain steps of conformity assessment do also require involvement of regulatory authorities (e.g. consultation of medicines authorities), digitalisation of these steps would also bring relevant benefit;
- Device developers and manufacturers have access to digitalised conformity assessment procedures. These procedures will become more efficient, less onerous, and more predictable, which will reduce costs and shorten the time to market access;
- Device developers and manufacturers, in particular small and medium-sized enterprises (SMEs), can direct a larger part of their resources towards the research and development of innovative devices.

HORIZON-HLTH-2025-01-TOOL-01: Enhancing cell therapies with genomic techniques

Source	Horizon Europe - Health
Maximum budget amount	10 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-TOOL-01?order=DESC&pageNumber=1&pageSize=50&sortBy=relevance&keywords=Enhancing%20cell%20therapies%20with%20genomic%20techniques&isExact
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

This topic aims at the design of engineered cells to address the current limitations of cellular therapies, such as delivery

efficiency, patient safety, in vivo persistence, desired therapeutic effect, immune tolerance and manufacturing workflows. The chosen approach should enable to control the characteristics, fate and function of the engineered cells from gene level onwards and thus lead to customised cells with improved therapeutic features.
The use of genetic engineering and in particular gene editing tools should be a key element in the design of the engineered cells. The therapeutic action should be based on the endogenous capabilities of the cells; the exogenous loading of cells with drugs (using the cells as drug carrier) is not in scope.
The engineered cells should be derived from human cells. Either stem cells or somatic cells may be used, but of allogeneic origin, thereby opening up the development of "off-the-shelf" cell therapeutics.

Expected Outcome:
- Biomedical scientists dispose of tools that allow them to engineer cells with specific therapeutic features.
- Improved methods and assays are available for biopharmaceutical developers.
- Clinicians will get access to innovative therapeutic approaches enabling them to treat conditions, where there are currently no or only insufficient therapeutic strategies.
- Cell engineering will be enriched and pave the way for novel personalised therapy options.

HORIZON-HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies

Source	Horizon Europe - Health
Maximum budget amount	13 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-TOOL-02?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2025-01-TOOL-02&isExactMatch=true&status=31094501,310
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

Currently, for the majority of secretome-based therapies, the main bottlenecks are: the incomplete understanding of their mode of action, their reproducibility due to a lack of standardised manufacturing processes and a lack of potency- and quality assurance assays.
Additional limitations are the characterisation of the bioactive factors and the optimisation of the delivery strategies.

Proposals submitted under this topic should tackle the above-mentioned issues and pave the way to secretome-based therapies that are safe, efficacious, and regulatory-approved for human use.

HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)

Source	Horizon Europe - Health
Maximum budget amount	17 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-TOOL-03?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2025-01-TOOL-03&isExactMatch=true&status=31094501,310
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

This topic will contribute to advancing research and providing new evidence on how these models contribute to and support biomedical research and its applicability towards more predictive and personalised medicine, while also defining use conditions, usability requirements and training needs of the researchers. It aims to cover existing gaps related to Generative AI in biomedical research, addressing both capabilities and existing limitations.

Research actions under this topic should include all the following activities, ensuring multidisciplinary approaches and a broad representation of stakeholders in the consortia (e.g.
industry, academia, healthcare professionals):
- Develop new or re-purpose existing Generative AI models for biomedical research across various medical fields and/or therapeutic indications.
- Develop a proof of concept with at least two use cases relevant for predictive and personalised medicine in different medical fields to demonstrate the scientific added value compared to currently used methods and/or potential future clinical utility of the Generative AI models in biomedical research
- Develop or revise existing methodologies to assess alignment with human values and the use cases of developed and/or repurposed Generative AI models, their applicability, performance, limitations and added value in biomedical research

HORIZON-HLTH-2025-01-TOOL-05: Boosting the translation of biotech research into innovative health therapies

Source	Horizon Europe - Health
Maximum budget amount	8 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-TOOL-05?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2025-01-TOOL-05&isExactMatch=true&status=31094501,310
Project duration	max. 4 years
Deadline	16.9.2025 17:00

Description

This topic aims to speed up the development of innovative biotechnology-based therapies by supporting the initial phases of clinical research. SMEs play a key role in the EU's potential to innovate,
with most biotechnology-derived drugs in development being progressed by SMEs and small biotech companies. This topic does not address the full clinical development needed to bring products to market but aims to support the critical transition phase from preclinical to clinical development by supporting the early clinical phases. A non-exhaustive list of biotechnology-derived therapies in scope include monoclonal antibodies, (therapeutic) vaccines, recombinant biomolecules, Advanced Therapy Medicinal Products (ATMPs), nanobased drugs, RNA therapies etc. Whole blood, blood components and other substances of human origin are not within the scope of this topic.

Proposals submitted under this topic should include all the following elements:
- A Clinical study either phase I, II or I/II depending on the appropriate stage of development.
- The proposal should convincingly demonstrate a significant economic potential of the final product(s) for the Single Market.
- A clearly defined exploitation plan, with a detailed proposed route to commercialisation, description of the intellectual property ownership and benefit for the SME(s).
- Justification of the patient populations that will benefit directly from the development of the therapies. Clinical indications where potentially large patient populations could benefit will be favoured.

HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders

Source	Horizon Europe - Health
Maximum budget amount	8 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-03-DISEASE-02-two-stage
Project duration	3 - 5 years
Deadline	1st round: 16.9.2025 17:00, 2nd round: 16.4.2026 17:00

Description

Mental, behavioural and neurodevelopmental disorders, that include for example severe depression, anxiety, schizophrenia, psychosis, post-traumatic stress disorder (PTSD), addictive behaviours (drugs[3], alcohol, gaming and others), obsessive-compulsive disorder, eating disorders and autism spectrum disorder are a high burden for patients, health systems and society, and remain unmet medical needs. More innovative, safer and more effective therapeutic and relapse-preventing solutions based on active substances are required, as for example for mental disorders many available treatments show modest efficacy, non-negligible side effects, discontinuation problems and high relapse rates. Additionally, other non-invasive multidisciplinary and/or transdiagnostic approaches (e.g. neurostimulation, neuroimaging, digital, non-pharmaceutical, psychotherapy, psychosocial) should be further developed to complement the therapeutic and relapse prevention solutions. These approaches aim to further improve health outcomes, self-determination, autonomy and quality of life in the long-term.

The disorders within the scope of this topic fall under Chapter 6 of the International Classification of Diseases76. Rare diseases are excluded.

HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorders

Source	Horizon Europe - Health
Maximum budget amount	7 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2025-01-ENVHLTH-01&isExactMatch=true&sta
Project duration	3 - 5 years
Deadline	1st round: 16.9.2025 17:00, 2nd round: 16.4.2026 17:00

Description

Research activities under this topic should explore evidence on the causal link between exposure to different pollutants (focusing on specific pollutants or a combination thereof) and the development or progression of neurological, neurodegenerative or neurodevelopmental diseases or disorders. Proposals can consider occupational, living and/or social environments and include one or more vulnerable, sensitive or exposed population groups.

Expected outcomes:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination "Living and working in a health-promoting environment". To that end, proposals under this topic should aim to deliver results that are directed, tailored and contributing to most of the following expected outcomes:
- Global and EU policies preventing and reducing the health impacts of pollution are supported with up-to-date scientific

evidence, tools and methodologies;
- Citizens are more protected by having a better insight into exposure to pollution and its impacts on brain health and adopting health enhancing behaviours;
- Public authorities, health stakeholders, the scientific community and the society at large have access to FAIR39 data on the link between pollution and brain health, particular windows of susceptibility to exposure and the impacts of pollution on the general population and vulnerable groups;
- Public authorities develop adequate evidence-based measures and guidelines to prevent and reduce the negative impacts of pollution in the development of brain disease.

HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health

Source	Horizon Europe - Health
Maximum budget amount	8 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage?order=DESC&pageNumber=1&pageSize=50&sortBy=relevance&keywords=Advancing%20knowledge%20on%20the%20impacts%20of%20mic
Project duration	3 - 5 years
Deadline	1st round: 16.9.2025 17:00, 2nd round: 16.4.2026 17:00

Description

Research activities under this topic should strengthen the evidence on the impacts of microand nanoplastics exposure on human health, considering living and working environments and different exposure routes (inhalation, ingestion and dermal exposure). Proposals should focus on realistic concentrations of tested particles and exposures to a variety of sizes, shapes and chemical compositions of MNPs materials and advance in the comparability between studies. Moreover, research activities should take into account recent policy developments, support relevant policy gaps and needs and support the work on standardisation of analytical methods.

HORIZON-HLTH-2025-03-IND-03-two-stage: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative ("breakthrough") devices

Source	Horizon Europe - Health
Maximum budget amount	8 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-03-IND-03-two-stage?order=DESC&pageNumber=1&pageSize=50&sortBy=relevance&keywords=Facilitating%20the%20conduct%20of%20multinational%20clini
Project duration	3 - 5 years
Deadline	1st round: 16.9.2025 17:00, 2nd round: 16.4.2026 17:00

Description

The focus of this topic is on multinational clinical studies of orphan devices and/or of highly innovative ("breakthrough") devices, including digital and Artificial Intelligence (AI) based tools and techniques.
The emphasis within rare disease research and innovation has predominantly centred on pharmaceuticals, leaving a noticeable gap in the support for developing orphan devices.
Orphan devices are specifically intended for use in rare diseases or conditions or in specific indications for rare cohorts of

patients with an otherwise non-rare disease or condition. As, by their nature, orphan devices are intended for use in a small number of individuals each year, often infants and children, generating clinical data within an appropriate period of time and conducting clinical nvestigations is especially challenging due to low patient recruitment volumes.
This topic targets those challenges by supporting multinational studies aiming to gather preor post-market clinical data to demonstrate the device's safety and performance (including determination of any undesirable side-effects and their acceptability when weighed against the expected clinical benefits).

The proposals should demonstrate that they address all the following activities for a device that is an orphan device or a highly innovative "breakthrough" device (or both), at any point of the pre-or post-market stage, including the development stage, with the overall purpose to generate data in support of CE marking under the Regulations on medical devices (MDR) or in vitro diagnostic medical devices (IVDR).

HORIZON-MISS-2025-02-CANCER-01: Sustained collaboration of national and regional cancer funders to support the Cancer Mission through translational research

Source	Horizon Europe - Missions
Maximum budget amount	5 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2025-02-CANCER-01?keywords=HORIZON-MISS-2025-02-CANCER&isExactMatch=true&status=31094501,31094502,31094503&frameworkProgramme=43108390&order=DES
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

The successful proposal should aim to deliver results that are directed and tailored towards and contribute to all the following expected outcomes:

National and regional cancer funders across Europe (i.e. representing Northern, Southern, Central, Eastern and Western Europe), based on a common strategic research and innovation agenda, deliver:
1. At least four transnational calls for proposals addressing translational cancer research, resulting in collaborative grants to academic investigator-led third parties;
2. Streamlined national, regional and foundation-based or charity-based practices in organising peer-reviewed translational cancer research and innovation funding between the partners, with attention to exploring novel funding schemes and initiatives as well as sustainability of a network of funders where appropriate;

Scope:
Common challenges in translational cancer research require effective transnational cooperation on prioritised efforts, leveraging national, regional and charity-based resources and appropriate funding schemes. Important achievements of translational cancer research funding by long-term collaboration of national and philanthropy funding organisations have been obtained by the TRANSCAN network under the Seventh Framework Programme for Research and Innovation (2007-2013) and Horizon 2020 (2014-2020).

More efforts are warranted to address the potential for sustainable coordination, the access to and sharing of research data to enhance the understanding of cancer as well as to further the alignment of national, regional and foundation or charity-based cancer research and innovation programmes and activities in Member States and Associated Countries. The EU contribution will not be used to co-fund the grants to third parties described hereunder.

HORIZON-MISS-2025-02-CANCER-02: Understanding the effects of environmental exposure on the risk of paediatric, adolescent and young adult cancers

Source	Horizon Europe - Missions
Maximum budget amount	7 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2025-02-CANCER-02?keywords=HORIZON-MISS-2025-02-CANCER&isExactMatch=true&status=31094501,31094502,31094503&frameworkProgramme=43108390&order=DES
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

Project results are expected to contribute to some of the following expected outcomes:
Researchers and health professionals will advance our understanding on how environmental, genetic and epigenetic, omics and other factors interact in determining the onset and development of cancers in children, adolescents and young adults and how they impact health outcomes in young cancer patients.
Policymakers and public health authorities have scientific evidence to improve prevention strategies to minimise the impacts of environmental factors on the development and progression of paediatric, adolescent and young adult cancers.
Researchers, innovators, and professionals from across different disciplines and sectors will support and contribute to the future UNCAN.eu research data platform by ensuring interoperability of data, new digital tools and models.

Scope:
This topic contributes to the Cancer Mission objectives by improving the understanding of the impact of environmental exposures including, their interaction with other relevant factors on cancer onset and progression and/or other relevant health outcomes along the cancer patient journey. The age group of interest for this topic includes children, adolescents and young adults (less than 40 years of age at first cancer diagnosis).

Applicants should take advantage of technological advances which have opened up new opportunities to collect, combine and analyse large datasets of diverse types, offering new possibilities to design epidemiological studies to understand the mechanistic contribution of environmental factors, in combination with other individual and contextual factors as appropriate. Innovative and data intensive approaches are expected for the identification of time windows of susceptibility[4] and of robust biomarkers of cumulative environmental exposure.

Proposals may envisage the creation of large cohort(s) by pooling and integrating existing retrospective studies in the areas of clinical research, exposome research, cancer registries and complementing with the new collection of other relevant data where needed (other omics data, digital pathology, behavioural and socio-economic data, clinical records etc.).

HORIZON-MISS-2025-02-CANCER-03: Innovative surgery as the cornerstone of affordable multi-modal therapeutic interventions benefitting cancer patients with locally advanced or metastatic disease

Source	Horizon Europe - Missions
Maximum budget amount	10 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2025-02-CANCER-03?keywords=HORIZON-MISS-2025-02-CANCER&isExactMatch=true&status=31094501,31094502,31094503&frameworkProgramme=43108390&order=DES
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

Expected Outcome:
Proposals under this topic should aim to deliver results that are directed and tailored towards, and to contribute to all of the following expected outcomes:

Patients have access to tailored, affordable, effective and–when appropriate–minimally-invasive surgery-centred, multi-modal treatment interventions targeting locally advanced or metastatic disease;
Researchers, innovators, SMEs and other professionals from different disciplines and sectors have access to innovative surgery-centred treatment technology and medical devices for further improvements and validation;
National healthcare providers, policymakers and authorities in European regions, Member States and Associated Countries have the evidence to implement affordable surgery-centred treatment solutions that benefit cancer patients with locally advanced or metastatic disease in their healthcare systems;

Scope:
Cancer surgery represents the main first line treatment for solid tumours. While cancer patients with locally advanced or metastatic disease across Europe are often excluded from clinical studies, they would benefit from access to tailored, affordable, innovative, surgery-centred interventions, which are adapted to an increasingly precision oncology healthcare landscape.

HORIZON-MISS-2025-02-CANCER-04: Investigator-initiated multinational early-stage innovative clinical trials for paediatric cancer

Source	Horizon Europe - Missions
Maximum budget amount	8 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2025-02-CANCER-04?keywords=HORIZON-MISS-2025-02-CANCER&isExactMatch=true&status=31094501,31094502,31094503&frameworkProgramme=43108390&order=DES
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes:

Children and adolescents with cancer have access to innovative, more effective, less toxic treatments–both in terms of acute toxicity and long-term late effects–and care solutions;
National healthcare providers, policymakers and authorities in European regions, Member States and Associated Countries have the scientific evidence to accelerate the implementation of affordable and accessible treatment and care solutions in their healthcare systems;
Researchers, innovators, and professionals from different disciplines and sectors ensure accessibility and re-usability of relevant trial data, to support the future UNCAN.eu research data platform, which is currently in preparation.

Scope:
This topic will contribute to the achievement of the Mission's objective to provide better treatments for cancer. The focus is on children (0-14 years of age, e.g. age of first cancer diagnosis) and/or adolescent (15-19 years of age, e.g. age of first cancer diagnosis) cancer patients.

Paediatric oncology has made considerable progress, increasing patient survival rates up to 80%; yet cancer remains the leading cause of death in children and adolescents. Progress in R&I to support the development of targeted cancer treatments for children has been rather limited. Over the past 20 years, less than 10% of new anti-cancer drugs have received marketing authorization for paediatric use, resulting in limited availability of innovative therapies to treat paediatric cancers. This is even more striking when cancers with poor prognosis are considered.

Most of the treatments currently used for paediatric cancers have been developed to treat adult cancers; in addition, young cancer patients and survivors very often experience adverse late-effects due to the high toxicity of treatments. Clinical tools used to evaluate treatment outcomes (e.g. tools to assess toxicity, radiological response, quality of life etc.), are also derived from adult oncology and therefore suboptimal;

This situation mostly reflects the fact that paediatric cancers are rare, and their biology is different to adult cancers. The relatively low number of cases warrants the implementation of multinational academic-initiated clinical trials to accelerate the development of innovative, more effective and less toxic treatments.

HORIZON-MISS-2025-02-CANCER-05: Pragmatic clinical trials to enhance the quality of life of older cancer patients (65 years and older) through nutrition

Source	Horizon Europe - Missions
Maximum budget amount	5 mil EUR
Funding (%)	100
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2025-02-CANCER-05?keywords=HORIZON-MISS-2025-02-CANCER&isExactMatch=true&status=31094501,31094502,31094503&frameworkProgramme=43108390&order=DES
Project duration	3 - 5 years
Deadline	16.9.2025 17:00

Description

Proposals under this topic should aim to deliver results that are directed and tailored towards, and to contribute to all of the following expected outcomes:
Older cancer patients have access to and benefit from tailored nutritional care-oriented interventions as part of routine treatment or care interventions, which improves treatment outcomes, alleviates disease symptoms and side effects and enhances their survival and quality of life;
National healthcare providers, policymakers and authorities in European regions, Member States and Associated Countries have the evidence to implement tailored nutritional care as part of routine cancer treatment or care interventions in their healthcare systems, including in everyday medical practice.

Scope:
Nutrition is of particular concern in older cancer patients due to issues like malabsorption, which is linked to adverse outcomes (such as mortality and decreased quality of life). Moreover, cancer incidence and mortality and prevalence predictions suggest a considerable increase of older cancer patients, who are also underrepresented in clinical studies. Hence, older cancer patients across Europe would benefit from access to optimised nutritional care-oriented interventions, to improve treatment outcomes, alleviate disease symptoms and side effects, thereby enhancing their survival and quality of life.

Pragmatic clinical trials address treatment optimisation by evaluating treatment effectiveness, i.e. the effect of treatment in routine (real-world) clinical practice.

IBRO - Parenthood Grants

Source	International Brain Research Organization (IBRO)
Maximum budget amount	4 000 USD
Funding (%)	100
Link	https://ibro.org/open-calls/
Project duration	
Deadline	15.8.2025 23:59

Description

Applicants should be early career principal investigators (maximum 7 years in this role).
- Any extended breaks from research (e.g. previous maternity or adoption leave) are accepted and should be justified in the application.
Applicants must have at least one published, peer-reviewed paper in at least the capacity of the corresponding author.
Applicants or their partner must either
- be pregnant (at least 4 months),
- have given birth in the last four months before the grant application deadline, or
- be close to adoption, assuming the role of the primary caregiver.

IOCB Tech - Voucher program to bridge funding gaps in clinical research

Source	Nadační fond IOCB Tech (Martina Roesel Memorial Grant)
Maximum budget amount	200 000 CZK
Funding (%)	100
Link	https://nf-iocbtech.cz/en/projects/118/voucher-program-to-bridge-funding-gaps-in-clinical-research
Project duration	not set
Deadline	30.11.2025 23:59

Description

The program aims to support individual steps in clinical research projects that address critical health challenges and are linked directly or indirectly to clinical settings.
The proposed research activity must represent a necessary linking part of ongoing research that cannot be covered from other pre-planned budgets. The application must properly justify why other funding cannot be used. Collaboration with healthcare facilities (if the applicant does not represent a hospital) is obligatory to ensure the clinical character of the research.

Leveraging Europe's Expertise to accelerate Cell Therapy for Type 1 Diabetes (HORIZON-JU-IHI-2025-11-04-two-stage)

Source	Innovative Health Initiative (IHI)
Maximum budget amount	8 825 000 EUR
Funding (%)	
Link	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-JU-IHI-2025-11-04-two-stage?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&isExactMatch=true&status=31094501,31094502&programmePart=43108406,43
Project duration	3 - 5 years
Deadline	1st round: 9.10.2025 17:00, 2nd round: 29.4.2026 17:00

Description

The action under this topic is expected to achieve the following impacts:
- to support the widespread adoption of beta-cell therapy, ensuring long-term efficacy, accessibility, and integration into healthcare systems;
- to accelerate the development of stem cell-based therapies through advancements in manufacturing, preclinical models, regulatory alignment, and predictive tools;
- to strengthen Europe's position as a leader in beta-cell therapy by fostering innovation hubs and clinical networks;
- scientific and regulatory progress will advance regenerative medicine for other metabolic and autoimmune disorders beyond T1D;
- patients, healthcare providers, regulators, policymakers, and industry stakeholders will all benefit from improved treatments, clearer guidelines, and increased investment;
- boosting European industrial competitiveness by driving innovation in cell-based therapies, fostering cross-sector collaboration, and enhancing Europe's global leadership in regenerative medicine.
These impacts are expected to advance IHI JU's objectives of improving healthcare quality, accessibility, and sustainability while contributing to European health policies and initiatives.

Major projects 2026 (partner only)

Source	Alzheimer's Research UK
Maximum budget amount	350 000 GBP
Funding (%)	100
Link	https://www.alzheimersresearchuk.org/grants/major-project/
Project duration	up to 5 years
Deadline	1.9.2025 23:59

Description

The Major Project grant scheme funds intermediate to large-scale research projects. Research questions should be framed to understand/diagnose/treat/ reduce risk of Alzheimer's disease and other dementias. The lead applicant and point of contact must be based in a UK academic/research institution. However, the application can include researchers or institutions outside the UK.
This scheme is not designed to cover:
- Clinical trials and opportunities to research 'add ons' to ongoing clinical trials
- Drug discovery or development

Martina Roeselová Memorial Grant 2026

Source	Nadační fond IOCB Tech (Martina Roesel Memorial Grant)
Maximum budget amount	150 000 CZK
Funding (%)	100
Link	https://nf-iocbtech.cz/aktuality/131/pametni-grant-martiny-roeselove-prijima-zadosti-na-rok-2026-a-nove-se-otevira-i-humanitnim-a-spolecenskym-vedam
Project duration	1 year
Deadline	19.9.2025 23:59

Description

Applications for the Martina Roeselová Fellowship are open to Ph.D. students and postdoctoral researchers caring for a preschool child or children while actively pursuing a career in natural sciences at a university or at a non-university research organization in the Czech Republic.

The grant applications must be in English and must include:

- a description of the family situation and the intended use of the grant (max 500 words)
- a plan of professional activities for the year (max 500 words)
- a curriculum vitae of the applicant with an overview of selected publications and conference presentations (approx. 2 pages)
- letter of recommendation from supervisor or immediate supervisor

NSF - Active Funding Opportunities

Source	National Science Foundation (NSF)
Maximum budget amount	
Funding (%)	
Link	https://www.nsf.gov/funding/pgm_list.jsp?org=NSF&ord=date
Project duration	
Deadline	Continuous

Description

NOTE: for US applicants only, can be used for US students comming to CZ.

The International Research Experiences for Students (IRES) program supports international research and research-related activities for U.S. science and engineering students. The IRES program contributes to development of a diverse, globally-engaged workforce with world-class skills. IRES focuses on active research participation by undergraduate or graduate students in high quality international research, education and professional development experiences in NSF-funded research areas.

This solicitation features three mechanisms; proposers are required to select one of the following tracks to submit their proposal.

Track I focuses on the development of world-class research skills in international cohort experiences. Track II is dedicated to targeted, intensive learning and training opportunities that leverage international knowledge at the frontiers of research. Track III calls for U.S. institutional partnerships and coalitions to develop and evaluate innovative models for high-impact, large-scale international research and professional development experiences for graduate students, as individuals or groups.

(1) IRES - Track I: IRES Sites (IS) projects engage a group of undergraduate and/or graduate students in active high quality collaborative research at an international site with mentorship from researchers at a host lab. IRES Sites must be organized around a coherent intellectual theme that may involve a single discipline or multiple disciplines funded by NSF.

(2) IRES - Track II: Advanced Studies Institutes (ASI) are intensive short courses with related activities that engage advanced graduate students in active learning and research at the frontiers of knowledge. ASIs typically range in length from ten to twenty-one days and must be held outside the United States. ASIs must have a compelling rationale for their international location and should involve distinguished active researchers in the target field from the U.S. and abroad. ASIs should enable students to develop skills and broaden professional networks, leveraging international participation and complementary resources (expertise, facilities, data, field site, etc.) for mutual benefit.

(3) IRES - Track III: New Concepts in International Graduate Experience (IGE) projects propose, implement, and evaluate creative ideas for catalyzing the development of globally engaged U.S. scientists and engineers at the graduate student level. The IGE IRES track invites professional societies and organizations in the U.S. directly associated with science and engineering education or research activities to propose innovative large-scale programs to provide high-quality international research and/or research-related professional development experiences for U.S. graduate students as individuals or groups. The proposed experiences should enhance transferable skills and expand professional networks. Graduate students recruited from a broad, diverse applicant pool should travel to non-U.S. locations for periods of several weeks to a semester for immersive experiences under the mentorship of appropriate collaborators in the U.S. and foreign locations. The proposed international professional development model may focus on research or research-related activities in any NSF-funded area(s). Proposals that utilize, leverage and potentially expand existing global networks and infrastructure are encouraged.

Student participants supported by IRES funds must be citizens, nationals, or permanent residents of the United States.

Students do not apply directly to NSF to participate in IRES activities. Students apply to NSF-funded investigators who receive IRES awards. To identify appropriate IRES projects, students should consult the directory of active IRES awards at https://www.nsf.gov/awardsearch/advancedSearchResult?WT.si_n=ClickedAbstractsRecentAwards&WT.si_x=1&WT.si_cs=1&WT.z_pims_id=12831&ProgEleCode=7727&BooleanElement=Any&BooleanRef=Any&ActiveAwards=true&#results

Open Science II (partner only)

Source	OP JAK
Maximum budget amount	
Funding (%)	
Link	https://opjak.cz/vyzvy/vyzva-c-02_24_030-open-science-ii/
Project duration	
Deadline	31.10.2025 23:59

Description

The aim of the call is to support discipline-specific and interdisciplinary activities within the framework of the implementation of the European Open Science Cloud initiative (hereinafter also “EOSC”) in the Czech Republic in accordance with the conceptual document “Architecture of EOSC Implementation in the Czech Republic”.

Specifically, the call will support the development of thematic/discipline repositories and their integration into the National Data Infrastructure (hereinafter also “NDI”) environment, the development and application of appropriate metadata models, standards and other tools and instruments increasing the searchability, accessibility, interoperability and reusability of research data (i.e. ensuring FAIR principles within and between disciplines, including specifics for sensitive data).

The call will further support the connection of these activities with international activities in order to ensure transnational interoperability and reduce barriers to intra-disciplinary and interdisciplinary access and use of research data on a European and global scale.

Visegrad Grants 2025

Source	International Visegrad Fund
Maximum budget amount	not specified
Funding (%)	100
Link	https://www.visegradfund.org/apply/grants/visegrad-grants/
Project duration	max 18 months
Deadline	1.10.2025 12:00

Description

Visegrad Grants is a grant program run and financed by the International Visegrad Fund, aimed at fostering cooperation between the V4 countries (Czechia, Hungary, Poland, Slovakia) via supporting ideas for sustainable regional cooperation. Projects must address at least one of the objectives of the grant program´s seven focus areas:
- Culture and Common Identity
- Education and Capacity Building
- Innovation, R&D, Entrepreneurship
- Democratic Values and the Media
- Public Policy and Institutional Partnership
- Regional Development, Environment and Tourism
- Social Development

Visegrad Strategic Grants 2025

Source	International Visegrad Fund
Maximum budget amount	not specified
Funding (%)	100
Link	https://www.visegradfund.org/apply/grants/strategic-grants/
Project duration	min. 12 months, max. 36 months
Deadline	1.10.2025 12:00

Description

Visegrad Strategic Grants is a grant program run and financed by the International Visegrad Fund aimed at fostering cooperation among the Visegrad Group (V4) countries (Czechia, Hungary, Poland, Slovakia) via supporting major projects for sustainable regional cooperation and serving, inter alia, the development of civil society, the improvement of mutual awareness among the V4 societies, and the promotion of the V4 region in line with the annual priorities defined jointly by the current and the upcoming V4 Presidency (the country in chair of the Visegrad Group):
Promoting volunteering in the V4 region
- Intensifying cross-border volunteering in the V4 region and/or improving conditions for both volunteers and the respective host institutions.
Promoting shared values
- Strengthening relations between civil societies in the Visegrad region in the context of the 25th anniversary of the Visegrad Fund's establishment. Supporting projects that promote shared cultural and historical values.
Supporting water management and flood protection cooperation in the region
- Promoting joint water management and flood protection initiatives. Fostering collaboration on disaster preparedness and climate resilience across Visegrad and neighbouring countries.

Visegrad+ Grants 2025

Source	International Visegrad Fund
Maximum budget amount	
Funding (%)	100
Link	https://www.visegradfund.org/apply/grants/visegrad-plus-grants/
Project duration	max 18 months
Deadline	1.10.2025 11:59

Description

Projects must develop meaningful cooperation and ensure the active involvement of at least 3 V4 countries and 1 entity from the Eastern Partnership region (EaP) or the Western Balkans countries (WB) at minimum (3xV4 + 1xEaP/WB format). However, if the applicant is from one of the EaP or WB countries, it is enough to involve two V4 countries in the project consortium, if another EaP/WB country is also involved (2xV4 + 2xEaP/WB format).
EXCEPTION from the partnership rules for Ukrainian entities, applicable until further notice: Applicants can apply with 2 partners from a different V4 country each without involving another country from the EaP or WB region (1xUA + 2xV4 format)
Visegrad+ Grants should be implemented in the EaP or WBs region, and/or have a strong impact on local communities in at least one of those countries
To apply for Visegrad+ Grants, your project must address one of the objectives of the grant program from the seven focus areas eligible for funding (more information on the link)

Wellcome - Discovery Awards 2025 (partner only)

Source	Wellcome (partner only)
Maximum budget amount	not specified
Funding (%)	100
Link	https://wellcome.org/research-funding/schemes/wellcome-discovery-awards
Project duration	usually 8 years
Deadline	1st round: 25.11.2025 23:59, 2nd round: 20.5.2026 23:59

Description

This scheme provides funding for established researchers and teams from any discipline who want to pursue bold and creative research ideas to deliver significant shifts in understanding that could improve human life, health, and wellbeing. The research can be in a single discipline or multidisciplinary.
The lead applicant must be based in UK, Republic of Ireland or Low- or middle-income country. Co-applicants can be at any career stage and based anywhere in the world, apart from mainland China.

Wellcome - Discovery Awards 2026 (partner only)

Source	Wellcome (partner only)
Maximum budget amount	not specified
Funding (%)	100
Link	https://wellcome.org/research-funding/schemes/wellcome-discovery-awards
Project duration	usually 8 years
Deadline	1st round: 26.3.2026 23:59, 2nd round: 20.9.2026 23:59

Description

This scheme provides funding for established researchers and teams from any discipline who want to pursue bold and creative research ideas to deliver significant shifts in understanding that could improve human life, health, and wellbeing.

The research can be in a single discipline or multidisciplinary.
The lead applicant must be based in UK, Republic of Ireland or Low- or middle-income country. Co-applicants can be at any career stage and based anywhere in the world, apart from mainland China.

widerAdvance Facility

Source	Horizon Europe - WIDERA
Maximum budget amount	
Funding (%)	
Link	https://www.wideradvance.eu/
Project duration	
Deadline	Continuous

Description

The WiderAdvance Facility project (https://www.wideradvance.eu/) is a new initiative under the Horizon Europe programme (Widening component), aiming to increase the impact of research results and support their dissemination and exploitation. It targets research organisations from Widening countries (including the Czech Republic) that are currently participating or have previously participated in Widening projects under Horizon 2020 or Horizon Europe. Specifically, the following actions are eligible:

COST Actions;
ERA Chairs;
ERA Talents;
Excellence Hubs;
European Excellence Initiative;
Hop-on Facility;
Pathways to Synergies;
Teaming for Excellence (Phase 2 in Horizon 2020);
Teaming for Excellence (Stage 2 in Horizon Europe);
Twinning;
Twinning for Western Balkans;
Widening/ERA Fellowship (H2020/HE).

The WiderAdvance Facility offers tailored services in dissemination and exploitation (D&E) to research teams (RTs) as well as research managers and administrators (RMAs) working with key exploitable results (KERs) from Widening projects. These services include: market interest validation, IPR protection and management, standardisation, effective communication with various target groups including investors, partner search, and access to follow-up funding.

By the end of 2028, a total of 12 cut-off dates will be announced under a continuously open call, with the aim to support up to 750 research outputs arising from Widening projects.